Skip to content
Screener

Aardvark Therapeutics, Inc. AARD Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue-
EPS-$0.99Miss by $0.12
EPS estimate-$0.87

Next report

Nov 12, 2026 (in a month)
EPS estimate-$0.74

Financials

Q1 2026

Income statement

See full
Revenue-—
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$82.25M—
Enterprise value$20.15M—

Returns & leverage

See full
Return on equity-58.8%—
Debt / equity0×0.0×
Current ratio8.1×-17.8×

FAQ

When did Aardvark Therapeutics, Inc. report Q1 2026 earnings?
Aardvark Therapeutics, Inc. (AARD) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Aardvark Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Aardvark Therapeutics, Inc. reported revenue of - and eps of $-0.99 for Q1 2026.
Did Aardvark Therapeutics, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.87 by $0.12.
How did Aardvark Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 39.4% from $-0.71.
Where can I find Aardvark Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-210664) and the 10-Q periodic report (0001193125-26-210675) directly on SEC EDGAR. The filing index links above go to sec.gov.